Cost-effectiveness Comparison of Dalpiciclib and Abemaciclib Combined with an Aromatase Inhibitor As First-Line Treatment for HR+/ HER2− Advanced Breast Cancer
Expert Review of Pharmacoeconomics & Outcomes Research（2024）
Key words
Abemaciclib,aromatase inhibitor,cost-effectiveness,dalpiciclib,HR+/HER2-advanced breast cancer
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined